To assess fetal risk after pregnancy exposure to natalizumab in women with multiple sclerosis (MS), with a specific focus on spontaneous abortion (SA) and congenital anomalies (CA).
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks / Portaccio, E., Annovazzi, P., Ghezzi, A., Zaffaroni, M., Moiola, L., Martinelli, V., Lanzillo, R., Brescia Morra, V., Rinaldi, F., Gallo, P., Tortorella, C., Paolicelli, D., Pozzilli, C., De Giglio, L., Cavalla, P., Cocco, E., Marrosu, M.G., Patti, F., Solaro, C., Bellantonio, P., et al.. - In: NEUROLOGY. - ISSN 0028-3878. - 90:10(2018), pp. e823-e831-e831. [10.1212/WNL.0000000000005067]
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks
Lanzillo, RobertaMembro del Collaboration Group
;Brescia Morra, VincenzoMembro del Collaboration Group
;
2018
Abstract
To assess fetal risk after pregnancy exposure to natalizumab in women with multiple sclerosis (MS), with a specific focus on spontaneous abortion (SA) and congenital anomalies (CA).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
